

Referencias

1. Quesada I, Todorova MG, Alonso-Magdalena P, Beltrá M, et al. Glucose induces opposite intracellular Ca²⁺ concentration oscillatory patterns in identified alpha- and beta-cells within intact human islets of Langerhans. *Diabetes*. 2006;55:2463-9.
2. Brissova M, Fowler MJ, Nicholson WE, Chu A, et al. Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. *J Histochem Cytochem*. 2005;53:1087-97.
3. Steiner DF, James DE. Cellular and molecular biology of the beta cell. *Diabetologia*. 1992;35 (Suppl 2):S41-8
4. Goodner CJ, Walike BC, Koerker DJ, Ensinnck JW, et al. Insulin, glucagon, and glucose exhibit synchronous, sustained oscillations in fasting monkeys. *Science*. 1977;195:177-9.
5. Melani F, Ryan WG, Rubenstein AH, Steiner DF. Proinsulin secretion by a pancreatic beta-cell adenoma. Proinsulin and C-peptide secretion. *N Engl J Med*. 1970;283:713-9.
6. Horwitz DL, Starr JJ, Mako ME, Blackard WG, et al. Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. *J Clin Invest*. 1975;55:1278-83.
7. Wollheim C.: "Glucose recognition and other signalling events in insulin secretion. In: New Horizons in Diabetes Mellitus Edit. Schwartz C.I. and Born GVR. Rapid Science. Pub. London 1996 pg. 28-38
8. Freychet P, Roth J, Neville DM Jr. Insulin receptors in the liver: specific binding of (125 I) insulin to the plasma membrane and its relation to insulin bioactivity. *Proc Natl Acad Sci U S A*. 1971;68:1833-7.
9. Ebin Y, Ellis L, Jarnagin K, Edery M, et al. The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. *Cell*. 1985;40:747-58.
10. Ullrich A, Bell JR, Chen EY, Herrera R, et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. *Nature*. 1985;313:756-61.
11. Hubbard SR, Wei L, Ellis L, Hendrickson WA. Crystal structure of the tyrosine kinase domain of the human insulin receptor. *Nature*. 1994;372:746-54.
12. Baldissera FG, Holst JJ. Glucagon-related peptides in the human gastrointestinal mucosa. *Diabetologia*. 1984;26:223-8.
13. Bataille D, Tatemoto K, Gespach C, Jörnvall H, et al. Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejunum-ileum. Characterization of the peptide. *FEBS Lett*. 1982;146:79-86.
14. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. *Nature*. 1983;304:368-71.
15. Deacon CF, Johnson AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. *J Clin Endocrinol Metab*. 1995;80:952-7.
16. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. *Endocrinology*. 1999;140:5356-63.
17. Wang F, Adrian TE, Westermark GT, Ding X, et al. Islet amyloid polypeptide tonally inhibits beta-, alpha-, and delta-cell secretion in isolated rat pancreatic islets. *Am J Physiol*. 1999;276:E19-24.
18. Quesada I, Tudurí E, Ripoll C, Nadal A. Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes. *J Endocrinol*. 2008;199:5-19.

19. Holst JJ. The physiology of glucagon-like peptide 1. *Physiol Rev.* 2007;87:1409-39.
20. Kido Y, Nakae J, Accili D. Clinical review 125: The insulin receptor and its cellular targets. *J Clin Endocrinol Metab.* 2001;86:972-9.
21. Brelje TC, Scharp DW, Sorenson RL. Three-dimensional imaging of intact isolated islets of Langerhans with confocal microscopy. *Diabetes.* 1989;38:808-14.
22. Ding WG, Renström E, Rorsman P, Buschard K, Gromada J. Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca²⁺-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. *Diabetes.* 1997;46:792-800.
23. Ahrén B. Autonomic regulation of islet hormone secretion—implications for health and disease. *Diabetologia.* 2000;43:393-410.
24. Ma X, Zhang Y, Gromada J, Sewing S, et al. Glucagon stimulates exocytosis in mouse and rat pancreatic alpha-cells by binding to glucagon receptors. *Mol Endocrinol.* 2005;19:198-212.
25. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care.* 2011;34 (Suppl 1):S62-9.
26. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. *N Engl J Med.* 1994;331:1428-36.
27. van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. *Physiol Rev.* 2011;91:79-118.
28. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. *Nature.* 2010;464:1293-300.
29. Cooper JD, Smyth DJ, Smiles AM, Plagnol V, et al. Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. *Nat Genet.* 2008;40:1399-401.
30. Concannon P, Erlich HA, Julier C, Morahan G, et al; Type 1 Diabetes Genetics Consortium. Type 1 diabetes: evidence for susceptibility loci from four genome-wide linkage scans in 1,435 multiplex families. *Diabetes.* 2005;54:2995-3001.
31. Casares S, Brumeanu TD. Insights into the pathogenesis of type 1 diabetes: a hint for novel immunospecific therapies. *Curr Mol Med.* 2001;1:357-78.
32. Gillespie KM. Type 1 diabetes: pathogenesis and prevention. *CMAJ.* 2006;175:165-70.
33. Dahlquist GG, Patterson C, Soltesz G. Perinatal risk factors for childhood type 1 diabetes in Europe. The EURODIAB Substudy 2 Study Group. *Diabetes Care.* 1999;22:1698-702.
34. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. *Med Clin North Am.* 2004;88:787-835
35. Rizza RA. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. *Diabetes.* 2010;59:2697-707.
36. Poitout V, Amyot J, Semache M, Zarrouki B, et al. Glucolipototoxicity of the pancreatic beta cell. *Biochim Biophys Acta.* 2010;1801:289-98.
37. Kaneto H, Matsuoka TA, Nakatani Y, Kawamori D, et al. Oxidative stress and the JNK pathway in diabetes. *Curr Diabetes Rev.* 2005;1:65-72.
38. Wajchenberg BL. beta-cell failure in diabetes and preservation by clinical treatment. *Endocr Rev.* 2007;28:187-218.
39. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes.* 2009;58:773-95.
40. Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?. *Diabetes.* 2010;59:1117-25.

41. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. *Endocrinol Metab Clin North Am.* 2010;39:481-97.
42. DIAMOND Project Group. Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. *Diabet Med.* 2006;23:857-66.
43. SEARCH for Diabetes in Youth Study Group, Liese AD, D'Agostino RB Jr, Hamman RF, et al. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. *Pediatrics.* 2006;118:1510-8
44. Lévy-Marchal C, Patterson CC, Green A; EURODIAB ACE Study Group. Europe and Diabetes. Geographical variation of presentation at diagnosis of type I diabetes in children: the EURODIAB study. *European and Diabetes. Diabetologia.* 2001;44 (Suppl 3):B75-80.
45. Aschner P. Epidemiología de la diabetes en Colombia. *Av Diabetol.* 2010;26:95-100
46. Mayer-Davis EJ, Bell RA, Dabelea D, D'Agostino R Jr, et al; SEARCH for Diabetes in Youth Study Group. The many faces of diabetes in American youth: type 1 and type 2 diabetes in five race and ethnic populations: the SEARCH for Diabetes in Youth Study. *Diabetes Care.* 2009;32 (Suppl 2):S99-101.
47. Tobón GJ, Arango A, Abad V, García J, et al. Clinical and immunological characteristics of type 1 diabetes mellitus in a northwestern Colombian population. *Diabetes Res Clin Pract.* 2006;72:170-5.
48. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care.* 2004;27:1047-53.
49. Forouhi NG, Wareham NJ. Epidemiology of Diabetes. *Medicine* 2010;38:602-606.
50. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract.* 2010;87:4-14.
51. Vargas H. Diabetes Mellitus. Una revisión. *Rev Fac Ciencias de la Salud* 2008;10:9-78. Separata Especial.
52. Escobedo J, Buitrón LV, Velasco MF, Ramírez JC, Hernández R, Macchia A, Pellegrini F, Schargrodsky H, Boissonnet C, Champagne BM; CARMELA Study Investigators. High prevalence of diabetes and impaired fasting glucose in urban Latin America: the CARMELA Study. *Diabet Med.* 2009;26:864-71.
53. Han TS, Lean MEJ. Metabolic Syndrome. *Medicine* 2011;39:24-31.
54. Organización Panamericana de la Salud. Guías ALAD de diagnóstico, control, y tratamiento de la Diabetes mellitus Tipo 2, Año 2009.
55. Aschner P, King H, Triana de Tornado M, Rodríguez BM. Glucose intolerance in Colombia. A population-based survey in an urban community. *Diabetes Care.* 1993;16:90-3.
57. Villegas A, Botero JF, Arango IC, et al. Prevalencia del Síndrome Metabólico en El Retiro, Colombia. *IATREIA.* 2003;16:291-297.
58. Alayón AN, Sedán CA. Prevalencia de desórdenes del metabolismo de los glúcidos y perfil del diabético en Cartagena de Indias (Colombia), 2005. *Salud Uninorte.* 2006;22:20-28.
59. LeRoith D, Taylor S, Olefsky JM. Diabetes Mellitus: a fundamental and clinical text. Lippincott Raven 2005.
60. Guías ALAD de diagnóstico, control y tratamiento de la Diabetes Mellitus Tipo 2, 2010.
61. Diagnóstico y manejo de la diabetes mellitus tipo 2 en adultos. www.icsi.org

62. Leahy JL, Hirsch IB, Peterson KA, Schneider D. Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus. *J Clin Endocrinol Metab.* 2010;95:4206-16.
63. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, et al; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. *Endocr Pract.* 2007;13 (Suppl 1):1-68.
64. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. *Diabet Med.* 2006;23:579-93.
65. Eschwege E, Richard JL, Thibault N, Ducimetière P, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. *Horm Metab Res Suppl.* 1985;15:41-6.
66. Stratton IM, Adler AI, Neil HA, Matthews DR, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UK-PDS 35): prospective observational study. *BMJ.* 2000;321:405-12.
67. Nathan DM, Cleary PA, Backlund JY, Genuth SM, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med.* 2005;353:2643-53.
68. American Diabetes Association. Standards of medical care in diabetes-2010. *Diabetes Care.* 2010;33 (Suppl 1):S11-61.
69. Adler AI, Erqou S, Lima TA, Robinson AH. Association between glycated haemoglobin and the risk of lower extremity amputation in patients with diabetes mellitus-review and meta-analysis. *Diabetologia.* 2010;53:840-9.
70. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. *Rev Endocr Metab Disord.* 2010;11:31-9.
71. Pignone M, Alberts MJ, Colwell JA, Cushman M, et al; American Diabetes Association; American Heart Association; American College of Cardiology Foundation. Aspirin for primary prevention of cardiovascular events in people with diabetes. *J Am Coll Cardiol.* 2010;55:2878-86.
72. Mattila TK, de Boer A. Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus. *Drugs.* 2010;70:2229-45.
73. Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. *Int J Clin Pract.* 2006;60:1471-83.
74. Krentz AJ, Clough G, Byrne CD. Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications. *Diabetes Obes Metab.* 2007;9:781-91.
75. Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. *Mayo Clin Proc.* 2011;86:444-56.
76. García RG, Rincón MY, Arenas WD, Silva SY, et al. Hyperinsulinemia is a predictor of new cardiovascular events in Colombian patients with a first myocardial infarction. *Int J Cardiol.* 2011;148:85-90.
77. Ramírez F, García RG, Silva F, López-Jaramillo P, Villa-Roel C. Glucemia en ayunas alterada es el factor de riesgo más sensible de enfermedad aterosclerótica coronaria en pacientes colombianos con angina. *Acta Med Colomb* 2004; 29: 302-311.

78. Esposito K, Kastorini CM, Panagiotakos DB, Giugliano D. Prevention of type 2 diabetes by dietary patterns: a systematic review of prospective studies and meta-analysis. *Metab Syndr Relat Disord*. 2010;8:471-6.
79. Hamdy O, Goodyear LJ, Horton ES. Diet and exercise in type 2 diabetes mellitus. *Endocrinol Metab Clin North Am*. 2001;30:883-907.
80. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med*. 2001;344:1343-50.
81. Li G, Zhang P, Wang J, Gregg EW, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. *Lancet*. 2008;371:1783-9.
82. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346:393-403.
83. Ramachandran A, Snehalatha C, Mary S, Mukesh B, et al; Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). *Diabetologia*. 2006;49:289-97.
84. Perez M, Casas JP, Cubillos-Garzón LA, Serrano NC, et al Using waist circumference as a screening tool to identify Colombian subjects at cardiovascular risk. *Eur J Cardiovasc Prev Rehabil*. 2003;10:328-35.
85. Motta A, Hernández-Triana E. Obesidad central y el diagnóstico de síndrome metabólico en pacientes de la población colombiana. Tesis de grado Universidad del Rosario Bogotá 2006.
86. Weinstock RS, Teresi JA, Goland R, Izquierdo R, et al; IDEATel Consortium. Glycemic control and health disparities in older ethnically diverse underserved adults with diabetes: five-year results from the Informatics for Diabetes Education and Telemedicine (IDEATel) study. *Diabetes Care*. 2011;34:274-9.
87. Joosten MM, Chiuve SE, Mukamal KJ, Hu FB, et al. Changes in alcohol consumption and subsequent risk of type 2 diabetes in men. *Diabetes*. 2011;60:74-9.
88. Baliunas DO, Taylor BJ, Irving H, Roerecke M, et al Alcohol as a risk factor for type 2 diabetes: A systematic review and meta-analysis. *Diabetes Care*. 2009;32:2123-32.
89. Will JC, Galuska DA, Ford ES, Mokdad A, Calle EE. Cigarette smoking and diabetes mellitus: evidence of a positive association from a large prospective cohort study. *Int J Epidemiol*. 2001;30:540-6.
90. Rimm EB, Chan J, Stampfer MJ, Colditz GA, Willett WC. Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. *BMJ*. 1995;310:555-9.
91. Chase HP, Garg SK, Marshall G, Berg CL, et al. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. *JAMA*. 1991;265:614-7.
92. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care*. 1993;16:434-44
93. Nyenwe EA, Loganathan RS, Blum S, Ezuteh DO, et al. Active use of cocaine: an independent risk factor for recurrent diabetic ketoacidosis in a city hospital. *Endocr Pract*. 2007;13:22-9.
94. Fisher L, Skaff MM, Mullan JT, Arean P, et al. Clinical depression versus distress among patients with type 2 diabetes: not just a question of semantics. *Diabetes Care*. 2007;30:542-8.

95. Gonzalez JS, Fisher L, Polonsky WH. Depression in diabetes: have we been missing something important?. *Diabetes Care*. 2011;34:236-9.
96. Rodriguez. Marin J, *Psicología social de la salud*. Madrid. Sintesis 1995.
97. Vinaccia S, Fernández H, Escobar O, Calle E, et al. Calidad de vida y conducta de enfermedad en pacientes con diabetes mellitus tipo II. *Suma Psicológica* 2006;13:15-31. dialnet.unirioja.es
98. Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. *J Clin Endocrinol Metab*. 2008;93 (Suppl 1):S9-30.
99. Ellis SE, Speroff T, Dittus RS, Brown A, et al. Diabetes patient education: a meta-analysis and meta-regression. *Patient Educ Couns*. 2004;52:97-105.
100. Norris SL, Engelgau MM, Narayan KM. Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials. *Diabetes Care*. 2001;24:561-87.
101. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet*. 1998;352:837-53.
102. Stratton IM, Adler AI, Neil HA, Matthews DR, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*. 2000;321:405-12.
103. ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. *Am J Cardiol*. 2007;99:21i-33i.
104. Abraira C, Duckworth W, McCarren M, Emanuele N, et al; VA Cooperative Study of Glycemic Control and Complications in Diabetes Mellitus Type 2. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. *J Diabetes Complications*. 2003;17:314-22.
105. Study rationale and design of ADVANCE: action in diabetes and vascular disease-preterax and diamicron MR controlled evaluation. *Diabetologia*. 2001;44:1118-20.
106. Gerstein HC, Riddle MC, Kendall DM, Cohen RM, et al; ACCORD Study Group. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol*. 2007;99:34i-43i.
107. Nathan DM, Buse JB, Davidson MB, Ferrannini E, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2009;32:193-203.
108. Aschner P, Kipnes MS, Luceford JK, Sanchez M, et al; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. *Diabetes Care*. 2006;29:2632-7.
109. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. *Diabetes Res Clin Pract*. 2007;76:132-8.
110. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. *Diabetes Obes Metab*. 2008;10:376-86.
111. Reasner C, Olansky L, Seck TL, Williams-Herman DE, et al. Initial therapy with the Fixed – Dose Combination (FDC) of sitagliptin and Metformin (Janumet) in Patient with Type 2 Diabetes Mellitus Provides Superior Glycemic Control

- and HbA1c Goal Attainment with Lower Rates of Abdominal Pain and Diarrhea versus Metformin Alone. Poster ADA congress 69th Scientific Sessions.
112. Wilcox R, Kupfer S, Erdmann E; PROactive Study investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitazone Clinical Trial In macro Vascular Events (PROactive 10). *Am Heart J.* 2008;155:712-7.
 113. Williams-Herman D, Johnson J, Teng R, Luo E, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. *Curr Med Res Opin.* 2009;25:569-83.
 114. Guía de Práctica Clínica sobre Diabetes tipo 2. Agencia de Evaluación de Tecnologías Sanitarias del País Vasco. España. Jul 2008.
 115. Medical guidelines for clinical practice for the management of Diabetes Mellitus. American Association of Clinical Endocrinologists. May 2007
 116. Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Canadian Diabetes Association. Canada. Sep 2008
 117. Goudswaard AN, Furlong NJ, Rutten GE, Stolk RP, Valk GD. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. *Cochrane Database Syst Rev.* 2004 Oct 18;(4):CD003418.
 118. Siebenhofer A, Plank J, Berghold A, Jeitler K, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. *Cochrane Database Syst Rev.* 2006 Apr 19;(2):CD003287.
 119. Horvath K, Jeitler K, Berghold A, Ebrahim SH, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. *Cochrane Database Syst Rev.* 2007 Apr 18;(2):CD005613.
 120. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. *Diabetes Care.* 2005;28:950-5.
 121. Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. *CMAJ.* 2009;180:400-7.
 122. American Diabetes Association. Gestational diabetes mellitus. *Diabetes Care.* 2004;27 (Suppl 1):S88-90.
 123. O'Sullivan JB, Mahan CM. Criteria for the oral glucose tolerance test in pregnancy. *Diabetes.* 1964;13:278-85.
 124. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. *Am J Obstet Gynecol.* 1982;144:768-73.
 125. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care.* 2010;33 (Suppl 1):S62-9.
 126. HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, et al. Hyperglycemia and adverse pregnancy outcomes. *N Engl J Med.* 2008;358:1991-2002.
 127. International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care.* 2010;33:676-82.
 128. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care.* 2011;34 (Suppl 1):S62-9.
 129. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med.* 1998;15:539-53.

130. Crowther CA, Hiller JE, Moss JR, McPhee AJ, et al; Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. *N Engl J Med.* 2005;352:2477-86.
131. Landon MB, Spong CY, Thom E, Carpenter MW, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A multicenter, randomized trial of treatment for mild gestational diabetes. *N Engl J Med.* 2009;361:1339-48.
132. Metzger BE, Buchanan TA, Coustan DR, de Leiva A, et al. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. *Diabetes Care.* 2007;30 (Suppl 2):S251-60.
133. Silva JC, Pacheco C, Bizato J, de Souza BV, et al. Metformin compared with glyburide for the management of gestational diabetes. *Int J Gynaecol Obstet.* 2010;111:37-40.
134. Moore LE, Clokey D, Rappaport VJ, Curet LB. Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. *Obstet Gynecol.* 2010;115:55-9.
135. Serlin DC, Lash RW. Diagnosis and management of gestational diabetes mellitus. *Am Fam Physician.* 2009;80:57-62.
136. Programa educativo para personas con diabetes (Nice Guidance dic. 2008)
137. Funnell MM, Brown TL, Childs BP, Haas LB, et al. National standards for diabetes self-management education. *Diabetes Care.* 2010;33 (Suppl 1):S89-96.
138. Guía de practicas clínicas sobre diabetes mellitus (DM2), marzo /2010 ministerio de protección social – Fundación Santa Fé.
139. Módulos de educación diabetológica IDF 2007. www.idf.org.
140. Chiasson JL, Aris-Jilwan N, Bélanger R, Bertrand S, et al. Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar state. *CMAJ.* 2003;168:859-66.
141. Campbell KB, Braithwaite SS. Hospital Management of Hyperglycemia. *Clinical Diabetes* 2004;22:81-88
142. Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, et al; American Diabetes Association. Hyperglycemic crises in diabetes. *Diabetes Care.* 2004;27 (Suppl 1):S94-102.
143. SM Morshatal. Diabetic Ketoacidosis and Hyperglycemic non-ketotic coma. En: International Textbook of Diabetes Mellitus. K.G.M.M. Alberti et al editors. John Wiley, Oxford 1992:1151-1164.
144. AM Fleckman. Diabetic ketoacidosis. En: Endocrine Crises. K.P. Ober Editor. Endocr and Metab Clin of North Am. Vol 22, 1993: 181-208.